You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
Dose Forms (% of Sales by Lead ing 5):<br />
90-95%<br />
Prin ci pal Prod ucts:<br />
SANDOZ CO-AMOXYCLA (pen i cil lin broad spec -<br />
trum)<br />
ACC 200 (ex pec to rant)<br />
SANDOZ LEVOFLOXACI (fluoroquinolone)<br />
FLUZOL (antifungal sys temic)<br />
DOBUTREX (car diac stim u lant non-glycoside)<br />
Ther a peu tic Range:<br />
antibacterials sys temic 23%<br />
psycholeptics 7%<br />
an al ge sics 6%<br />
car diac ther a pies 6%<br />
cough and cold prep a ra tions 6%<br />
Lead ing Dose Forms:<br />
coated tab lets 36%<br />
tab lets 34%<br />
cap sules 13%<br />
vi als 9%<br />
in fu sions 3%<br />
SOUTH KOREA<br />
CIBA VI SION<br />
Full Name: CIBA Vi sion (Ko rea) Ltd.<br />
Street Ad dress: 6fl. Se oul City Tower Bldg., 581,<br />
Namdaemunro 5ga, Joong-gu, Se oul 100-803<br />
Tel: +82 2 768-9000<br />
Fax: +82 2 768-9299<br />
Home Page: www.cibavision.co.kr<br />
De scrip tion: Packager/as sem bler, im porter, ex -<br />
porter, dis trib u tor, pro moter, sales/detailer. Prod -<br />
uct ranges in clude: oph thal mic prod ucts, op ti cal<br />
in stru ments. Es tab lished 1997. 30 phar ma ceu ti -<br />
cal employees in 2006.<br />
Rep re sen ta tives/De tail ers (Pharm, Num -<br />
ber): 13 (2006)<br />
Con tacts (Pharm): Chair man: Ohn Jong-Seok<br />
NOVARTIS<br />
Full Name: Novartis Ko rea Ltd<br />
Street Ad dress: 7fl. Se oul City Tower Bldg., 581,<br />
Namdaemunro 5ga, Joong-gu, Se oul 100-803<br />
Tel: +82 2 768-9000<br />
Fax: +82 2 785-1939<br />
Home Page: www.novartis.co.kr<br />
De scrip tion: Im porter, dis trib u tor, pro moter,<br />
sales/detailer. Im ports, dis trib utes, sells/de tails<br />
for other com pa nies. Prod uct ranges in clude:<br />
phar ma ceu ti cal prod ucts (branded, pre scrip tion,<br />
non-pre scrip tion), hos pi tal pharmaceuticals, di -<br />
etetic/nu tri tional prod ucts, oph thal mic prod ucts,<br />
vet er i nary pharmaceuticals. Es tab lished 1997.<br />
Di vi sions include: General; Special.<br />
Con tacts (Pharm): Chair man: Frank Bobe, Pe -<br />
ter Maag; Com mer cial Op er a tions: Will Charles;<br />
Mar ket Re search: K.R. Song; Re search & De vel -<br />
op ment: J.W. Ko; Gen eral Con tact: Seung-Hye<br />
Ha<br />
Sub sid iary of: Novartis, Swit zer land (99%)<br />
(group: Novartis, Swit zer land); Dong Wha, South<br />
Ko rea (1%)<br />
Phar ma ceu ti cal Sales: US$ 320-330 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 50-55%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 70-75%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
90-95%<br />
Prin ci pal Prod ucts:<br />
GLIVEC (antineoplastic other)<br />
DIOVAN (an gio ten sin-II an tag o nist plain)<br />
CODIOVAN (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
SANDIMMUN NEORAL (immunosuppressive<br />
agent)<br />
COTAREG (an gio ten sin-II an tag o nist com bi na -<br />
tion)<br />
Ther a peu tic Range:<br />
renin-an gio ten sin sys tem agents 33%<br />
antineoplastics 19%<br />
immunosuppressive agents 9%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions 5%<br />
antiepileptics 5%<br />
Lead ing Dose Forms:<br />
coated tab lets 73%<br />
cap sules 10%<br />
tab lets 6%<br />
in fu sions 3%<br />
liq uids 3%<br />
SPAIN<br />
BEXAL<br />
Full Name: Bexal Farmaceutica S.A.<br />
Street Ad dress: Centro Empresarial Osa Mayor,<br />
Av/Osa Mayor no 4, Area B, Aravaca, 28023 Ma -<br />
drid<br />
Tel: +34 91 548 84 04<br />
Fax: +34 91 548 84 05<br />
Email: bexal@bexal.es<br />
Home Page: www.bexal.es<br />
De scrip tion: De vel oper, im porter, dis trib u tor,<br />
pro moter, sales/detailer. Im ports for other com -<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 208
Change language